MAPT and tauopathy: We identified proteins associated with disease status and AD-related phenotypes (Clinical Dementia Rating® [CDR®], CSF Aβ42/Aβ40, amyloid-PET, and tau-PET tauopathy), which were used to identify disease-specific biomarkers and perform pathway analyses.